23andMe Investor Presentation Deck
Segment Information and Reconciliation of Non-GAAP
Financial Measures
Note: Fiscal year ends March 31.
(unaudited)
(in $K)
Segment Revenue
Consumer & Research Services
Therapeutic
Total Revenue
Segment Adjusted EBITDA
Consumer & Research Services
Therapeutics
Unallocated Corporate
Total Adjusted EBITDA
Reconciliation of Net Loss to Adjusted EBITDA
Net Loss
Adjustments:
Interest (income), net
Other (income) expense, net
Change in fair value of warrant liabilities
Income tax benefit
Depreciation and amortization
Amortization of acquired intangible assets
Stock-based compensation expense
Acquisition-related costs
Total Adjusted EBITDA
Nine Months Ended December 31,
FY2022
Amount
$171,334
$171,334
($33,232)
(57,046)
(30,692)
($120,970)
($147,946)
(213)
(39)
(32,989)
(3,512)
14,188
2,898
37,473
9,170
($120,970)
FY2021
Amount
$155,290
$48
$155,338
($4,925)
(38,886)
(21,554)
($65,365)
($116,606)
(195)
(1,318)
15,532
37,222
($65,365)View entire presentation